Prebiotics/synbiotics as natural alternatives for brain development and aging - focus on nutrigenomic and direct effects: a systematic review.

Nutr NeurosciApr 24, 2026 (epub)
Clinical ResearchNeurologyPsychiatry

Lilian Vanessa Penha Gonçalves, Pedro Fernandes Gusmão de Holanda, Arthur Vinicius da Silva Cabral et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examines the role of prebiotics and synbiotics in brain development and neurodegenerative diseases, analyzing 79 studies including human and animal research. The review highlights their potential as nutraceuticals influencing epigenetic mechanisms. Notably, prebiotics may restore normal interactions between systemic diseases and brain function.

Key findings

  • 79 articles were selected from an initial 503, including 47 animal studies, 18 in vitro studies, and 13 human studies.
  • Prebiotics and synbiotics are identified as essential nutrients for brain development.
  • The review emphasizes the need for further studies on prebiotic intervention in the brain epigenome.

Why it matters

Understanding the impact of prebiotics and synbiotics on brain health could lead to innovative therapeutic strategies for neurodegenerative diseases, enhancing cognitive function and overall brain development.

Source

PubMed · PMID 42028746

Published in Nutr Neurosci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.